Mymetics Corporation (MYMX)

OTCMKTS · Delayed Price · Currency is USD
0.0003
0.00 (0.00%)
At close: Dec 12, 2025
-70.00%
Market Cap 46.00
Revenue (ttm) 564.14K
Net Income (ttm) -12.24M
Shares Out 151.88K
EPS (ttm) -80.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 143
Average Volume 387
Open 0.0003
Previous Close 0.0003
Day's Range 0.0003 - 0.0003
52-Week Range 0.0003 - 0.0003
Beta 2.29
RSI 37.20
Earnings Date n/a

About Mymetics

Mymetics Corporation engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company’s product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, and malaria. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; and national institutes of health. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corpora... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1990
Employees 2
Stock Exchange OTCMKTS
Ticker Symbol MYMX
Full Company Profile

Financial Performance

In 2022, Mymetics's revenue was 1.03 million, an increase of 139.07% compared to the previous year's 430,000. Losses were -4.81 million, 1.59% more than in 2021.

Financial numbers in EUR Financial Statements

News

There is no news available yet.